Invention Application
- Patent Title: DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS
-
Application No.: US16802822Application Date: 2020-02-27
-
Publication No.: US20210107979A1Publication Date: 2021-04-15
- Inventor: Yi ZHANG , Thomas John VAN BLARCOM , Siler PANOWSKI , Silvia K. TACHEVA-GRIGOROVA , Barbra Johnson SASU
- Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
- Applicant Address: US CA South San Francisco; US NY New York
- Assignee: ALLOGENE THERAPEUTICS, INC.,PFIZER INC.
- Current Assignee: ALLOGENE THERAPEUTICS, INC.,PFIZER INC.
- Current Assignee Address: US CA South San Francisco; US NY New York
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C12N15/63 ; A61P35/00
Abstract:
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
Public/Granted literature
- US11673953B2 DLL3 targeting chimeric antigen receptors and binding agents Public/Granted day:2023-06-13
Information query
